文献速递白血病造血干细胞移植与细胞治疗

KTE-X19治疗成人复发难治急性淋巴细胞白血病的ZUMA-3一期结果

KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results.
PubMed 文献 · Blood · 2021-01-01

ZUMA-3是一项1/2期研究,评估自体抗CD19 CAR-T细胞KTE-X19治疗成人复发难治B细胞急性淋巴细胞白血病。一期部分报告:45例可评估患者中,未观察到剂量限制性毒性,83%在1×10^6/kg剂量下达到完全缓解,中位缓解持续时间17.6个月;≥3级细胞因子释放综合征和神经事件发生率分别为31%和38%,修订管理后安全性改善。

要点

  • KTE-X19在成人R/R B-ALL中显示高缓解率,1×10^6/kg剂量下完全缓解率83%。
  • ≥3级CRS和NE发生率分别为31%和38%,修订AE管理后3级CRS 33%、3级NE 11%。
  • 中位随访22.1个月,1×10^6/kg剂量下中位缓解持续时间17.6个月。

核心结论

  • KTE-X19治疗成人复发难治B-ALL提供了高缓解率和可耐受的安全性。

研究设计与样本

  • ZUMA-3为1/2期研究,报告一期结果,评估自体抗CD19 CAR-T细胞KTE-X19。
  • 入组54例,45例接受单次输注,剂量为2×10^6、1×10^6或0.5×10^6细胞/kg,中位年龄46岁(范围18-77岁)。
  • 主要终点为输注后28天内剂量限制性毒性(DLT)发生率。

主要发现

  • 可评估DLT队列中未发生DLT。
  • ≥3级细胞因子释放综合征(CRS)和神经事件(NE)分别发生在31%和38%的患者中。
  • 在1×10^6细胞/kg剂量下,总完全缓解率为83%;所有患者中为69%。
  • 所有缓解患者微小残留病(MRD)均不可测。
  • 中位随访22.1个月(范围7.1-36.1个月),1×10^6细胞/kg剂量下中位缓解持续时间为17.6个月(95%CI 5.8-17.6个月),所有患者为14.5个月(95%CI 5.8-18.1个月)。

关键数值与推荐

  • 修订AE管理(NE更早使用类固醇,托珠单抗仅用于CRS)在1×10^6细胞/kg剂量下评估。
  • 修订管理下9例患者中,33%发生3级CRS,11%发生3级NE,无4级或5级NE。
  • 完全缓解率与CAR-T细胞扩增相关。

临床怎么用

  • KTE-X19可用于成人R/R B-ALL,推荐在1×10^6细胞/kg剂量下结合修订AE管理进行2期研究。

局限性

  • 本文报告一期结果,样本量有限。
  • 修订AE管理仅在9例患者中评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ZUMA-3 is a phase 1/2 study evaluating KTE-X19, an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in adult relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). We report the phase 1 results. After fludarabine-cyclophosphamide lymphodepletion, patients received a single infusion of KTE-X19 at 2 × 106, 1 × 106, or 0.5 × 106 cells per kg. The rate of dose-limiting toxicities (DLTs) within 28 days after KTE-X19 infusion was the primary end point. KTE-X19 was manufactured for 54 enrolled patients and administered to 45 (median age, 46 years; range, 18-77 years). No DLTs occurred in the DLT-evaluable cohort. Grade ≥3 cytokine release syndrome (CRS) and neurologic events (NEs) occurred in 31% and 38% of patients, respectively. To optimize the risk-benefit ratio, revised adverse event (AE) management for CRS and NEs (earlier steroid use for NEs and tocilizumab only for CRS) was evaluated at 1 × 106 cells per kg KTE-X19. In the 9 patients treated under revised AE management, 33% had grade 3 CRS and 11% had grade 3 NEs, with no grade 4 or 5 NEs. The overall complete remission rate correlated with CAR T-cell expansion and was 83% in patients treated with 1 × 106 cells per kg and 69% in all patients. Minimal residual disease was undetectable in all responding patients. At a median follow-up of 22.1 months (range, 7.1-36.1 months), the median duration of remission was 17.6 months (95% confidence interval [CI], 5.8-17.6 months) in patients treated with 1 × 106 cells per kg and 14.5 months (95% CI, 5.8-18.1 months) in all patients. KTE-X19 treatment provided a high response rate and tolerable safety in adults with R/R B-ALL. Phase 2 is ongoing at 1 × 106 cells per kg with revised AE management. This trial is registered at www.clinicaltrials.gov as #NCT02614066.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Shah BD, Bishop MR, Oluwole OO, et al. KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results. Blood. 2021. PMID: 33827116. doi:10.1182/blood.2020009098

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。